

# DClinSci Life Sciences University of Manchester

Rebecca Dearman

Life Sciences Programme Director for HSST

University of Manchester



The University of Manchester

# UoM Life Sciences Specialisms

Analytical Toxicology

Clinical Biochemistry

Clinical Immunology

Genetics

Histocompatibility & Immunogenetics

Microbiology

Molecular Pathology of Infection

Virology

# UoM Life Sciences Trainees

Cohort 1 (Sept 2020)

14 trainees doing C2, 13 trainees C1 only

Cohort 2 (includes 1 “new” pathway)(Sept 2020)

7 trainees doing C2, 4 trainees C1 only

## **C1/C2 changes to Section C**

Cohort 3 (Sept 2021)

13 trainees doing full DClSci; 5 doing Extended  
Innovation Proposal only

Cohort 4 (Sept 2022)

17 trainees in total; 6 doing Extended Innovation Proposal  
only (including some interrupts)

Cohort 5 (Sept 2023)

14 trainees in total; 2 doing Extended Innovation Proposal  
only

# The Structure of the DClinSci

## **Section A – Leadership & Management (approx 20%)**

Taught in Manchester for all trainees at  
Alliance Manchester Business School

## **Section B – Specialist Scientific Component (approx 30%)**

FRCPath part 1

(By special agreement with the Royal College of Pathologists)

## **Section C – Research & Innovation (approx 50%)**

Overseen by University and carried out in workplace setting  
with input from academic and NHS workplace supervisors

This section *can* fulfil the research component of FRCPath part 2

(By special agreement with the Royal College of Pathologists for some specialisms)

## **Section A – Leadership & Management**

A1 Professionalism and Professional Development in the Healthcare Environment

A2 Theoretical Foundations of Leadership

A3 Personal and Professional Development to Enhance Performance

A4 Leadership and Quality Improvement in the Clinical and Scientific Environment

A5 Research and Innovation in Health and Social Care

Section C – Innovation  
Cohort 4

# Proposed Timeline for Extended Innovation Proposal (EIP)

30 <sup>th</sup> June 2019	EIP title submission appointment of academic supervisors
30 <sup>th</sup> September 2019	Planning meeting
30 <sup>th</sup> November 2019	Innovation proforma (300 words)
31 <sup>st</sup> December 2019	Optional formative 1500 words
31 <sup>st</sup> January 2020	Progress meeting
28 <sup>th</sup> February 2020	Literature review/business case submission
30 <sup>th</sup> April 2020	Feedback from supervisors on written component
May 2020	Lay presentation

# Proposed Timeline for Extended Innovation Proposal (EIP)

30 <sup>th</sup> June 2020	EIP title submission appointment of academic supervisors
30 <sup>th</sup> September 2020	Planning meeting
30 <sup>th</sup> November 2020	Innovation proforma (300 words)
31 <sup>st</sup> December 2020	Optional formative 1500 words
31 <sup>st</sup> January 2021	Progress meeting
28 <sup>th</sup> February 2021	Literature review/business case submission
30 <sup>th</sup> April 2021	Feedback from supervisors on written component
May 2021	Lay presentation

## Section C – Research & Innovation (approx 50%) Provisional Timeline for Full DClin Sci Cohort 4

15 <sup>th</sup> May 2019	proforma submission/appointment of academic supervisors
31 <sup>st</sup> July 2019	Royal College of Pathology approval*
30 <sup>th</sup> September 2019	Planning/expectation meeting optional draft Literature review 1500 words for feedback
31 <sup>st</sup> January 2020	Literature review submission
31 <sup>st</sup> March 2020	Progress meeting (1)
May 2020	Lay presentation
30 <sup>th</sup> September 2020	Progress meeting (2)
31 <sup>st</sup> March 2021	Progress meeting (3)
30 <sup>th</sup> September 2021	Thesis planning meeting
31 <sup>st</sup> March 2022	Thesis progress meeting (includes innovation business plan)
September 2022	End date (submission and viva)

**Timing subject to negotiations with Royal College**



## Section C – Research & Innovation (approx 50%) Proposed Timeline for Full DClin Sci cohort 5

31 <sup>st</sup> December 2019	research title/appointment of academic supervisors
28 <sup>th</sup> February 2020	proforma submission
31 <sup>st</sup> May 2020	Royal College of Pathology approval*
30 <sup>th</sup> September 2020	Planning/expectation meeting optional draft Literature review 1500 words for feedback
31 <sup>st</sup> January 2021	Literature review submission
31 <sup>st</sup> March 2021	Progress meeting (1)
May 2021	Lay presentation
30 <sup>th</sup> September 2021	Progress meeting (2)
31 <sup>st</sup> March 2022	Progress meeting (3)
30 <sup>th</sup> September 2022	Thesis planning meeting
31 <sup>st</sup> March 2023	Thesis progress meeting (includes innovation business plan)
September 2023	End date (submission and viva)

**Timing subject to negotiations with Royal College**

The aim of the proforma is in the first instance for the University to identify an Academic Supervisor and then for the Programme Director and Academic Supervisor to work with the Trainee to develop the research project. Therefore the information you provide should explain “The Big Picture” and why there is a gap in knowledge that needs to be addressed.

The research has to be novel and should not just be method adaptation although this can form part of the project if the whole approach then involves for example, evaluation using patients or patient samples. As guidance you should consider a project where the results are of publishable quality.

Where appropriate, the proforma is also sent to the Royal College of Pathologists to get approval of the project.

# Project Proposal Proforma

## **750-1000 words**

*Aims of the research (including background to the clinical need)*

*Principal research question(s)*

*Proposed project plan*

*Proposed methods*

*Potential impact of research*

*A summary of patient and public involvement in the research*

# Other Considerations

Ethics

Animal experimentation

Project funding

# DClinSci Assessment

- Literature Report assessed by Supervisor
- Lay Talk-oral assessed by Panel
- Research Project Examined by Thesis & *viva voce* (with external examiner)

# Literature Report

## **Aims of Report**

- review the literature providing the background to the research
- identify the importance of the research area and what is controversial
- formulate a hypothesis based on the literature
- Detail aims of project and relate them to the literature review
- critically evaluate the various experimental approaches and why specific approaches have been chosen for the project
- outline the relevance of the proposed project to the research area

# Literature Report

- Summative 5000 word (+/- 10%) Literature Review
- It should include a range of sources but must include primary sources (peer-reviewed journal articles).
- It should be well-structured with a good standard of scientific English and appropriately referenced.
- Figures and Tables are valuable
- NB: For those not doing DClSci there will also be an Innovation Proposal (5 x A4 pages)-see Website

# Literature Report-marking

- Marked by Workplace Supervisor and Academic Supervisor
- Check dates on eprog for Deadline of submission and outcome
- Feedback and marking will be completed by a month after submission.
- Each section should be marked as **Pass** or **Fail** only.
- If the two markers cannot agree on the overall outcome, the submission will be sent to a third marker at the discretion of the Programme Lead (depending on whether the disagreement is around academic or clinical content).
- Where the written project has been “failed” the trainee can resubmit once. The examiners must provide detailed feedback.



# Lay Presentation

- An **oral presentation** of the Research Project
- A key skill is the ability to present research ideas to a non-specialist audience
- the assessment will be carried out independent of the supervisory team
  - Programme Lead
  - Another Academic and External assessor
  - Lay Person